Copyright Reports & Markets. All rights reserved.

USA Cystic Fibrosis Therapeutics Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Cystic Fibrosis Therapeutics Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 CFTR Market Performance (Volume)
      • 2.1.2 Mucolytics Market Performance (Volume)
      • 2.1.3 PERT Market Performance (Volume)
      • 2.1.4 Anti-infectives Market Performance (Volume)
      • 2.1.5 Bronchodilators Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 CFTR Market Performance (Value)
      • 2.1.2 Mucolytics Market Performance (Value)
      • 2.1.3 PERT Market Performance (Value)
      • 2.1.4 Anti-infectives Market Performance (Value)
      • 2.1.5 Bronchodilators Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Hospitals Market Performance (Volume)
      • 3.1.2 Clinics Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Vertex Pharmaceuticals
      • 4.1.1 Vertex Pharmaceuticals Profiles
      • 4.1.2 Vertex Pharmaceuticals Product Information
      • 4.1.3 Vertex Pharmaceuticals Cystic Fibrosis Therapeutics Business Performance
      • 4.1.4 Vertex Pharmaceuticals Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.2 F. Hoffmann-La Roche
      • 4.2.1 F. Hoffmann-La Roche Profiles
      • 4.2.2 F. Hoffmann-La Roche Product Information
      • 4.2.3 F. Hoffmann-La Roche Cystic Fibrosis Therapeutics Business Performance
      • 4.2.4 F. Hoffmann-La Roche Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.3 AbbVie
      • 4.3.1 AbbVie Profiles
      • 4.3.2 AbbVie Product Information
      • 4.3.3 AbbVie Cystic Fibrosis Therapeutics Business Performance
      • 4.3.4 AbbVie Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.4 Gilead Sciences
      • 4.4.1 Gilead Sciences Profiles
      • 4.4.2 Gilead Sciences Product Information
      • 4.4.3 Gilead Sciences Cystic Fibrosis Therapeutics Business Performance
      • 4.4.4 Gilead Sciences Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.5 Novartis
      • 4.5.1 Novartis Profiles
      • 4.5.2 Novartis Product Information
      • 4.5.3 Novartis Cystic Fibrosis Therapeutics Business Performance
      • 4.5.4 Novartis Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.6 AstraZeneca
      • 4.6.1 AstraZeneca Profiles
      • 4.6.2 AstraZeneca Product Information
      • 4.6.3 AstraZeneca Cystic Fibrosis Therapeutics Business Performance
      • 4.6.4 AstraZeneca Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.7 Bayer
      • 4.7.1 Bayer Profiles
      • 4.7.2 Bayer Product Information
      • 4.7.3 Bayer Cystic Fibrosis Therapeutics Business Performance
      • 4.7.4 Bayer Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.8 Celtaxsys
      • 4.8.1 Celtaxsys Profiles
      • 4.8.2 Celtaxsys Product Information
      • 4.8.3 Celtaxsys Cystic Fibrosis Therapeutics Business Performance
      • 4.8.4 Celtaxsys Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.9 Pharmaxis
      • 4.9.1 Pharmaxis Profiles
      • 4.9.2 Pharmaxis Product Information
      • 4.9.3 Pharmaxis Cystic Fibrosis Therapeutics Business Performance
      • 4.9.4 Pharmaxis Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.10 ProQR Therapeutics
      • 4.10.1 ProQR Therapeutics Profiles
      • 4.10.2 ProQR Therapeutics Product Information
      • 4.10.3 ProQR Therapeutics Cystic Fibrosis Therapeutics Business Performance
      • 4.10.4 ProQR Therapeutics Cystic Fibrosis Therapeutics Business Development and Market Status
    • 4.11 PTC Therapeutics
    • 4.12 Alcresta Therapeutics
    • 4.13 AbbVie
    • 4.14 Gilead Sciences
    • 4.15 Novartis

    5 Market Performance for Manufacturers

    • 5.1 USA Cystic Fibrosis Therapeutics Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 USA Cystic Fibrosis Therapeutics Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 USA Cystic Fibrosis Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 USA Cystic Fibrosis Therapeutics Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Northeast Market Performance for Manufacturers
      • 6.1.1 Northeast Cystic Fibrosis Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 Northeast Cystic Fibrosis Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 Northeast Cystic Fibrosis Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 Northeast Cystic Fibrosis Therapeutics Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 Midwest Market Performance for Manufacturers
      • 6.2.1 Midwest Cystic Fibrosis Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 Midwest Cystic Fibrosis Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 Midwest Cystic Fibrosis Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 Midwest Cystic Fibrosis Therapeutics Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 South Market Performance for Manufacturers
      • 6.3.1 South Cystic Fibrosis Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 South Cystic Fibrosis Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 South Cystic Fibrosis Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 South Cystic Fibrosis Therapeutics Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 West Market Performance for Manufacturers
      • 6.4.1 West Cystic Fibrosis Therapeutics Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 West Cystic Fibrosis Therapeutics Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 West Cystic Fibrosis Therapeutics Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 West Cystic Fibrosis Therapeutics Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration

    7 USA Cystic Fibrosis Therapeutics Market Performance (Sales Point)

    • 7.1 USA Cystic Fibrosis Therapeutics Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 USA Cystic Fibrosis Therapeutics Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 USA Cystic Fibrosis Therapeutics Price (USD/Unit) by Regions 2013-2018
    • 7.4 USA Cystic Fibrosis Therapeutics Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 USA Cystic Fibrosis Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 Northeast Cystic Fibrosis Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 Midwest Cystic Fibrosis Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 South Cystic Fibrosis Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 West Cystic Fibrosis Therapeutics Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Hospitals Industry
    • 11.2 Clinics Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 USA Cystic Fibrosis Therapeutics Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 USA Cystic Fibrosis Therapeutics Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 Northeast Cystic Fibrosis Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 Midwest Cystic Fibrosis Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 South Cystic Fibrosis Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 West Cystic Fibrosis Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 Cystic Fibrosis Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Cystic Fibrosis Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Cystic Fibrosis Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.10 Cystic Fibrosis Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 CFTR Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Mucolytics Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 PERT Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.5 Anti-infectives Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Hospitals Sales and and Growth Rate 2019-2024
      • 12.4.3 Clinics Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 USA Cystic Fibrosis Therapeutics Price (USD/Unit) Trend 2019-2024
      • 12.5.2 USA Cystic Fibrosis Therapeutics Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split USA into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Cystic Fibrosis Therapeutics for these regions, from 2012 to 2023 (forecast), including
    Northeast
    Midwest
    South
    West

    USA Cystic Fibrosis Therapeutics market competition by top manufacturers/players, with Cystic Fibrosis Therapeutics sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Vertex Pharmaceuticals
    F. Hoffmann-La Roche
    AbbVie
    Gilead Sciences
    Novartis
    AstraZeneca
    Bayer
    Celtaxsys
    Pharmaxis
    ProQR Therapeutics
    PTC Therapeutics
    Alcresta Therapeutics
    Insmed Incorporated
    Savara
    Cyclacel Pharmaceuticals

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    CFTR
    Mucolytics
    PERT
    Anti-infectives
    Bronchodilators

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Cystic Fibrosis Therapeutics for each application, including
    Hospitals
    Clinics

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now